IP Library Granted Patent US 9,066,902
Granted Patent B2
US 9,066,902 · App. 13/387,489 · Granted Jun 30, 2015

Fatty acids as anti-inflammatory agents

Inventors: Bruce A. Freeman (Pittsburgh, PA); Francisco J. Schopfer (Pittsburgh, PA)
Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
A61K31/12A61K31/231A61K31/232
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,066,902
App. No.
13/387,489
Granted
Jun 30, 2015
Kind
B2
Abstract

Compounds of formula I and their metabolites are potent mediators of an inflammatory response: (I) where a, b, c, d, e, f, V, W, X, Y, R a , R a′ , R b , R b′ , R c , and R c′ are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.

Claims (41)

1. A pharmaceutical formulation comprising: an effective amount of a compound having a formula of:

wherein:

R 1 is a heterocyclyl;

is an optional double bond;

W is —OH, —C(O)H, —C(O), —C(O)R p , —COOH, —COOR p , —Cl, —Br, —I, —CF 3 , —CN, —SO 3 , —SO 2 R p , —SO 3 H, —NH 3 + , —NH 2 R p+ , —NR p R q R t , —NO 2 , ═O, ═NR p , ═CF 2 , or —CHF;

each V is, independently —CH or —C—, wherein:

V is —CH— when W is —OH, —H, —C(O)H, —C(O), —C(O)R p , —COON, —COOR p , —Cl, —Br, —I, —F, —CF 3 , —CN, —SO 3 , —SO 2 R p , —SO 3 H, —NH 3+ , —NH 2 R p+ , —NR p R q R t or —NO 2 ; or

V is —C— when W is ═O, ═NR p , ═CF 2 or ═CHF;

R p and R q are each, independently, H, (C 1 -C 8 ) alkyl, aryl, or (C 1 -C 8 ) haloalkyl;

R t is (C 1 -C 8 ) alkyl, aryl, or (C 1 -C 8 ) haloalkyl;

R b and R b′ are each independently, —H, —OH, —C(O)H, —C(O), —C(O)R p , —COOH, —COOR p , —Cl, —Br, —I, —F, —CF 3 , —CHF 2 , —CH 2 F, —CN, —SO 3 , —SO 2 R p , SO 3 H, —NH 3 + , —NH 2 R p+ , —NR p R q R t or —NO 2 , wherein:

R b and R b′ are not simultaneously non-hydrogen groups;

a is an integer between 5 and 15 inclusive, c is an integer from 1 and 15 inclusive, and f is an integer between 5 and 15 inclusive; and

a pharmaceutically acceptable carrier.

2. The formulation according to claim 1 , wherein W is —H, ═O or ═NR p .

3. The formulation according to claim 1 , wherein V is —CH— and W is —H.

4. The formulation according to claim 1 , wherein V is —C— and W is ═O.

5. The formulation according to claim 1 , wherein c is 1, V is —C—, and W is ═O.

6. The formulation according to claim 1 , wherein R b and R b′ , are each, independently, —H, —OH, —CN, or —NO 2 .

7. The formulation according to claim 1 , wherein R b and R b′ are each —H.

8. The formulation according to claim 1 , wherein a is 3.

9. The formulation according to claim 1 , wherein the pharmaceutically acceptable carrier comprises a solid, solution, powder, fluid emulsion, fluid suspension, semi-solid, or dry powder.

10. The formulation according to claim 1 , further comprising at least one pharmaceutically acceptable diluent, filler, disintegrant, binder, lubricant, surfactant, hydrophobic vehicle, water soluble vehicle, emulsifier, buffer, humectant, moisturizer, solubilizer, antioxidant, or preservative, or combinations thereof.

11. A compound having a formula of:

wherein:

R 1 is a heterocyclyl;

is an optional double bond;

W is —OH, —C(O)H, —C(O), —C(O)R p , —COOH, —COOR p , —Cl, —Br, —I, —CF 3 , —CN, —SO 3 , —SO 2 R p , —SO 3 H, —NH 3 + , —NH 2 R p+ , —NR p R q R t , —NO 2 , ═O, ═CF 2 , or —CHF;

each V is, independently —CH or —C—, wherein:

V is —CH— when W is —OH, —H, —C(O)H, —C(O), —C(O)RP, —COOH, —COORP, —Cl, —Br, —I, —F, —CF 3 , —CN, —SO 3 , —SO 2 RP, —SO 3 H, —NH 3+ , —NH 2 RP + , —NR p R q R t or —NO 2 ; or

V is —C— when W is ═O, ═NRP, ═CF 2 or ═CHF;

R p and R q are each, independently, H, (C 1 -C 8 ) alkyl, aryl, or (C 1 -C 8 ) haloalkyl;

R t is (C 1 -C 8 ) alkyl, aryl, or (C 1 -C 8 ) haloalkyl;

R b and R b′ are each independently, —H, —OH, —C(O)H, —C(O), —C(O)R p , —COOH, —COOR p , —Cl, —Br, —I, —F, —CF 3 , —CHF 2 , —CH 2 F, —CN, —SO 3 , —SO 2 R p , SO 3 H, —NH 3 + , —NH 2 R p+ , —NR p R q R t or NO 2 , wherein:

R b and R b′ are not simultaneously non-hydrogen groups;

a is an integer between 5 and 15 inclusive, c is an integer from 1 and 15 inclusive, and f is an integer between 5 and 15 inclusive.

12. The compound according to claim 11 , wherein W is ═O or ═NRP.

13. The formulation of claim 1 , wherein R 1 is a heteroaryl or a heterocycloalkyl.

14. The compound of claim 11 , wherein R 1 is a heteroaryl or a heterocycloalkyl.

15. The compound according to claim 11 , wherein V is —C— and W is ═O.

16. The compound according to claim 15 , wherein c is 1.

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 8, 2012
From: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027669/0040 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2012
From: FREEMAN, BRUCE A.; SCHOPFER, FRANCISCO J.
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 027670/0053 →
Continuity (2)
Provisional Application 61213946 · Jul 31, 2009
Related Publication 20120136034A1 · May 31, 2012